[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100498101":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":31,"responsibleParty":47,"collaborators":20,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":20,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":20,"enrollmentInfo":59,"targetDuration":20,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":20,"overallStatus":33,"whyStopped":20,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Shandong Cancer Hospital and Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"WX-0593","EXPERIMENTAL","The treatment will be administrated as neoadjuvant 8 weeks before surgery. After surgical intervention the treatment will be administered up to 2 years. Treatment will be discontinued in case of unacceptable toxicity or disease progression.",[13],"Drug: WX-0593 Tablets",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","WX-0593 Tablets","60 mg of WX-0593 tablets, once daily for 7 days, followed by 180 mg of WX-0593 tablets, once daily in a 28-days cycle.",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Pingping Song","CONTACT","18663776711","SPP128@126.com",{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},"Guodong Zhang","15701206264","zzkzgd@163.com",[32],{"facility":5,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Jinan","Shandong","250117","China","CN",{"type":40,"coordinates":41},"Point",[42,43],116.99722,36.66833,{"lat":43,"lon":42},[46],{"name":23,"role":24,"phone":20,"phoneExt":20,"email":20},{"type":48,"investigatorFullName":23,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"SPONSOR_INVESTIGATOR","Department director","100498101","phase-2-neoadjuvant-wx-0593-in-resectable-alk-positive-or-ros1-positive-non-small-cell-lung-cancer-100498101",false,"NCT05765877","Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer","Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer : a Single-arm, Exploratory Trial","Inclusion Criteria:\n\n* Histologically confirmed non-small cell lung cancer (NSCLC).\n* ALK-positive or ROS1-positive NSCLC in Stage IB-IIIA (according to the 8th American Joint Committee on Cancer TNM edition), as assessed by investigator.\n* Complete surgical resection of the primary NSCLC must be deemed achievable, as assessed by a MDT evaluation (which should include a thoracic surgeon, specialized in oncologic procedures).\n* ECOG Performance Status of 0-1.\n* At least one measurable lesion according to RECIST 1.1.\n* Adequate organ and marrow function.\n\nExclusion Criteria:\n\n* Prior treatment with any systemic anti-cancer therapy for NSCLC including chemotherapy, biologic therapy, immunotherapy, or any investigational drug.\n* Prior treatment with ALK TKI or ROS1 TKI.\n* Prior treatment with local radiotherapy.\n* Mixed small cell and NSCLC histology.\n* Patients who are candidates to undergo only segmentectomies or wedge resections.","ALL","18 Years",{"count":60,"type":61},26,"ESTIMATED","INTERVENTIONAL",[64],"PHASE2","This is a single-arm, exploratory trial to evaluate the efficacy and safety of neoadjuvant WX-0593 in patients with resectable ALK-positive or ROS1- positive non-small cell lung cancer(NSCLC).",[67],"Non-Small Cell Lung Cancer(NSCLC)","2025-06-11",{"date":70,"type":71},"2025-06-12","ACTUAL",{"date":73,"type":71},"2023-03-01",{"date":75,"type":61},"2029-03",{"name":23,"class":6},1]